Clinical Trial Update: PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the combination of Carilizumab, a PD-1 antibody, with Apatinib in unresectable stage III/IV mismatch repair-deficient gastric canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• Carilizumab (Carilizumab)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING